Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CCG 2961 A Phase III Study in Children with Untreated Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Trial Profile

CCG 2961 A Phase III Study in Children with Untreated Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary) ; Asparaginase (Primary) ; Busulfan (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Hydrocortisone (Primary) ; Idarubicin (Primary) ; Methotrexate (Primary) ; Tioguanine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 08 Dec 2020 Results from CCG-2961, AAML03P1, AAML0531 and AAML1031, assessing molecular characteristics and clinical relevance of NUP98 in Pediatric Acute Myeloid Leukemia, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 15 Jan 2013 Primary endpoints added as reported by ClinicalTrials.gov.
    • 10 Dec 2012 Results were presented at the 54th Annual Meeting of the American Society of Hematology (ASH) in December 2012.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top